2022-05-27T15:44:07-05:00 2021-09-30 814234542 BPM LLP 4200 BOHANNON DRIVE SUITE 250 MENLO PARK CA 940251021 990 2020-10-01 770207331 PALO ALTO VETERANS INSTITUTE FOR RESEARCH PALO 6502392800 3801 MIRANDA AVENUE PALO ALTO CA 94304 ELAINE STAATS CEO 6502392802 2022-05-24 1 ELAINE STAATS 999009999 CAROLYN R AMSTER P00189994 6508556800 2022-05-24 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z PAVIR ELAINE STAATS 3801 MIRANDA AVENUE PALO ALTO CA 94304 29467576 0 X WWW.PAVIR.ORG X 1988 CA ADVANCING VETERAN AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. 13 2 273 0 0 0 23851668 24470355 5633108 4876898 47815 16959 40051 35800 29572642 29400012 0 0 0 0 16710546 16053637 0 0 0 14478372 12065304 31188918 28118941 -1616276 1281071 12982406 15189973 6265277 7191146 6717129 7998827 X SEE SCHEDULE OPAVIR'S MISSION IS ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. PAVIR WORKS WITH MORE THAN 100 RESEARCHERS AND 215 STAFF TO SUPPORT BASIC SCIENCE AND CLINICAL RESEARCH TO REALIZE ITS MISSION. PAVIR'S RESEARCH SPANS THE INVESTIGATION OF DISEASES IN THE LABORATORY TO TESTING NEW DRUG TREATMENTS AND DEVELOPING IMPROVED MODELS OF HEALTH CARE DELIVERY. IN ADDITION TO A FOCUS ON BASIC SCIENCE AND CLINICAL RESEARCH, PAVIR'S RESEARCH ADDRESSES HEALTH CHALLENGES THAT HAVE BEEN FACED ESPECIALLY BY VETERANS, INCLUDING POST-TRAUMATIC STRESS DISORDER AND TRAUMATIC BRAIN INJURY, GERIATRIC MEDICINE, REHABILITATION, SLEEP AND OTHER VETERANS AND PUBLIC HEALTH DISEASES. PAVIR'S RESEARCHERS HAVE APPOINTMENTS AT THE VA PALO ALTO HEALTH CARE SYSTEM, AND MOST HOLD DUAL APPOINTMENTS AT THE STANFORD UNIVERSITY SCHOOL OF MEDICINE 0 0 1655602 1655602 TARGETED STRATEGIES TO ACCELERATE EVIDENCE-BASED PSYCHOTHERAPY (EBP) IMPLEMENTATION IN MILITARY. PRINCIPAL INVESTIGATORS: CRAIG S. ROSEN, PH.D. AND CARMEN P. MCLEAN, PH.D. THIS FOUR-YEAR STUDY, FUNDED BY THE DEPARTMENT OF DEFENSE, IS AIMED AT INCREASING USE OF EVIDENCE-BASED PSYCHOTHERAPIES (THERAPIES PROVEN EFFECTIVE IN RESEARCH) IN CLINICS ON MILITARY BASES. DESPITE EFFORTS TO TRAIN MILITARY PROVIDERS IN EFFECTIVE PSYCHOTHERAPIES FOR POSTTRAUMATIC STRESS DISORDER (PTSD), ONLY A MINORITY OF SERVICE MEMBERS RECEIVE THESE TREATMENTS. THIS TRIAL TESTS WHETHER A TAILORED PROCESS IMPROVEMENT APPROACH (USING A TOOLKIT FOR MATCHING SPECIFIC CHANGE STRATEGIES TO LOCAL BARRIERS) IS MORE EFFECTIVE THAN PROVIDER TRAINING ALONE IN EXPANDING THE PROPORTION OF PATIENTS WHO RECEIVE AN EBP. THE PROJECT, LED BY INVESTIGATORS AT THE NATIONAL CENTER FOR PTSD AND PALO ALTO VETERANS INSTITUTE FOR RESEARCH (PAVIR), INCLUDES COLLABORATORS FROM FIVE UNIVERSITIES AND EIGHT MILITARY TREATMENT FACILITIES. OBJECTIVES: TO TEST IN A STEPPED-WEDGE RANDOMIZED TRIAL WHETHER THE TARGETED ASSESSMENT AND CONTEXT-TAILORED IMPLEMENTATION OF CHANGE STRATEGIES (TACTICS) INCREASES USE OF EVIDENCE-BASED PSYCHOTHERAPY MORE THAN DOES PROVIDER TRAINING ALONE. SECONDARY OUTCOMES INCLUDE EFFECTS OF TACTICS ON AVERAGE IMPROVEMENT IN PTSD SYMPTOMS, AND SATISFACTION WITH THE TACTICS PROCESS. ACCOMPLISHMENTS: ALL STAFF HAVE BEEN HIRED, EIGHT MILITARY CLINICS REPRESENTING ALL SERVICE BRANCHES WERE RECRUITED AND ALL REGULATORY APPROVALS OBTAINED. PROVIDER TRAINING AND THE SUBSEQUENT PROCESS IMPROVEMENT INTERVENTION (TACTICS) HAS BEEN IMPLEMENTED AT ALL STUDY SITES. PROVIDER SURVEY DATA COLLECTION IS COMPLETED. CENTRALIZED EXTRACTION OF STUDY DATA IN COLLABORATION WITH THE DEFENSE HEALTH AGENCY IS ONGOING.POTENTIAL IMPACT: IF EFFECTIVE, TACTICS MAY REPRESENT A SCALABLE APPROACH TO ACCELERATING THE USE OF BEHAVIORAL HEALTH BEST PRACTICES IN MILITARY SETTINGS. 800160 NOVEL STRATEGIES TO COMBAT POST-TRAUMATIC OSTEOARTHRITIS (PTOA): GAIT RETRAINING TO REDUCE JOINT LOADING, INFLAMMATION, AND PTOA RISK AKA NOVEL STRATEGIES TO COMBAT POST-TRAUMATIC OSTEOARTHRITIS. PRINCIPAL INVESTIGATORS: CONSTANCE CHU, M.D. AND WILLIAM ROBINSON, M.D., PH.D.DRS. CONSTANCE CHU AND WILLIAM ROBINSON ARE CLINICIAN-SCIENTISTS WHOSE PROJECTS AT PAVIR REPRESENT TWO OF FIVE SYNERGISTIC PROJECTS INTEGRATING COMPLEX INTERACTIONS BETWEEN MECHANICAL, BIOLOGICAL, AND STRUCTURAL FACTORS TO PROVIDE INSIGHTS INTO THE PATHOGENESIS OF POST-TRAUMATIC OSTEOARTHRITIS (PTOA). THIS INTEGRATED PROGRAM EVALUATES AND OPTIMIZES NOVEL DIAGNOSTIC AND THERAPEUTIC STRATEGIES POISED FOR TRANSLATION INTO CLINICAL PRACTICE AND CONTRIBUTE NEW BIOMARKER, IMAGING AND THERAPEUTIC TARGETS FOR EARLY DETECTION AND STAGING OF JOIN DEGENERATION LEADING TO PTOA. PROJECT 1 DEFINES THE ROLE OF FIBRINOLYSIS IN THE DEVELOPMENT OF PTOA. THIS PROJECT EXAMINES THE HYPOTHESIS THAT DEREGULATION OF THE FIBRINOLYSIS SYSTEM DRIVES THE PATHOGENESIS OF PTOA BY PROMOTING INFLAMMATION AND CARTILAGE DEGRADATION. OBJECTIVES 1: PERFORM ELISA AND LUMINEX ASSAYS ON THE ANTERIOR CRUCIATE TEAR AND DEGENERATIVE MENISCAL TEAR CLINICAL COHORTS. 2: SURGICALLY INDUCE OA IN MICE AND ADMINISTER TRANEXAMIC ACID TREATMENT. 3: DESIGN AND PERFORM TRANEXAMIC ACID TREATMENT ON MICE SUBJECTED TO MOUSE OA. ACCOMPLISHMENTS: 1: THE RESEARCHERS IDENTIFIED DYSREGULATED TYPE II INFLAMMATORY MEDIATORS IN HUMAN PATIENTS WITH ACL AND DEGENERATIVE MENISCAL TEARS. 2: THE RESEARCH SHOWS THAT TRANEXAMIC ACID PREVENTS DEVELOPMENT OF OA. 3: THE RESEARCH SHOWS SOME BENEFIT OF TRANEXAMIC ACID TREATMENT WHEN TREATMENT IS STARTED 4 WEEKS AFTER JOINT INJURY, AND INCREASED BENEFIT WHEN STARTED 2 WEEKS AFTER SURGICAL JOINT INJURY.STATISTICAL TESTS ARE PERFORMED ON ALL EXPERIMENTAL DATA AND INCLUDE SIGNIFICANCE ANALYSIS OF MICROARRAYS (SAM) ANALYSIS OF MULTIPLEX CYTOKINE DATASETS (WHICH P < 0.05) AS WELL AS MANN WHITNEY TEST FOR MOUSE DATASETS (P<0.05 FOR KEY COMPARISONS).PROJECT 2 IS AN EARLY PHASE II DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO TEST THE HYPOTHESIS THAT TRANEXAMIC ACID AFTER JOINT INJURY WILL REDUCE MARKERS OF INFLAMMATION AND CARTILAGE DEGRADATION. IT WILL PROVIDE SCIENTIFIC GUIDANCE ON ANTERIOR CRUCIATE LIGAMENT TEAR (ACLT) SURGERY, CLINICAL OUTCOMES, AND ANALYSIS OF THE DATASETS. OBJECTIVES 1: DISCOVER THE DIFFERENCES IN SYNOVIAL FLUID LEVELS OF INFLAMMATORY & CARTILAGE BIOMARKERS. 2: TEST THE CELLS-BASED THERAPY IN ACL REGENERATION. 3: DISCOVER THE CHANGES IN BIOMARKERS IN CORRELATION WITH CARTILAGE HEALTH AFTER GAIT RE-TRAINING.ACCOMPLISHMENTS: 20 PATIENTS WITH ACUTE ACL WERE ENROLLED AND THEIR SAMPLES WERE COLLECTED AT THREE TIME POINTS. SAMPLES WILL BE ASSAYED FOR INFLAMMATORY FACTORS AND CYTOKINES. ANIMAL EXPERIMENTS WITH ACLT SURGERY HAVE BEEN CONDUCTED FOR THE FIRST 10 RATS. WE ARE IN THE PROCESS OF DOING THE NEXT 10 RATS TO DATE.WE WILL ENROLL AND COLLECT 50 PATIENTS' SAMPLES TO BE IN A LARGER COHORT AND ASSAY THE CYTOKINES IN WHOLE SET. THIS WAY, THE RESEARCH WILL GET ENOUGH STATISTICAL POWER TO CONCLUDE. STATICAL ANALYSIS BY A STATISTICIAN WILL BE PERFORMED ONCE OUR RECRUITMENT GOAL BASED ON A PRIORI POWER ANALYSIS IS REACHED. CURRENTLY, THE RESEARCHERS ARE RAMPING UP RECRUITMENT AND STRIVING TO COMPLETE DATA COLLECTION AND PROCESSING. 732930 ANTIMICROBIAL RESISTANCE AND HORIZONTAL GENE TRANSFER IN THE HUMAN GUT MICROBIOME IN RESPONSE TO AN ANTIBIOTIC. PRINCIPAL INVESTIGATOR: DAVID A. RELMAN, M.D.ANTIMICROBIAL RESISTANCE (AMR) IS AN INCREASINGLY PREVALENT AND SERIOUS PROBLEM WORLDWIDE. THE HUMAN GUT IS A HOTSPOT FOR BOTH THE EVOLUTION AND SPREAD OF AMR; COMMENSALS SERVE AS A SOURCE OF AMR FOR PATHOGENS VIA HORIZONTAL GUT TRANSFER (HGT). WE ARE STUDYING RESPONSES TO ANTIBIOTIC EXPOSURE IN THE HUMAN GUT MICROBIOTA IN VIVO, AS WELL AS IN COMPLEX STOOL-DERIVED SUBJECT-SPECIFIC COMMUNITIES IN VITRO, AT HIGH TEMPORAL RESOLUTION AND USING INNOVATIVE APPROACHES. WE LINK AMR AND OTHER MOBILE GENETIC ELEMENT (MGE)-ASSOCIATED GENES TO THEIR HOST CORE GENOMES USING HIGH THROUGHOUT CHROMOSOME CONFORMATION CAPTURE (HI-C) AND MONITOR THESE GENES AND ELEMENTS IN BACTERIAL HOSTS BEFORE, DURING AND AFTER ANTIBIOTIC EXPOSURE. THE SHORT TERM-OBJECTIVES OF THE PROPOSED WORK ARE TO CHARACTERIZE AND ASSESS THE CONTRIBUTIONS OF DE NOVO MUTATIONS AND HGT TO THE SPREAD AND DEVELOPMENT OF AMR IN THE HUMAN GUT MICROBIOTA DURING ANTIBIOTIC EXPOSURE. THE LONG-TERM OBJECTIVES ARE TO IMPROVE ANTIBIOTIC STEWARDSHIP BY IDENTIFYING CRITICAL EVENTS OR TRANSITIONS IN THE EVOLUTION AND DISSEMINATION OF AMR IN VIVO, AND THE FACTORS AND CONDITIONS THAT MAKE THOSE EVENTS LESS LIKELY.OBJECTIVES - 1. DETERMINE THE DISTRIBUTION OF AMR GENES IN THE GUT MICROBIOTA OF 60 HEALTHY HUMANS PRIOR TO A CIPROFLOXACIN EXPOSURE . 2. CHARACTERIZE THE EFFECTS OF CIPROFLOXACIN ON THE ABUNDANCE AND MOBILIZATION OF AMR GENES IN THE HUMAN GUT MICROBIOTA IN VIVO FROM THE SAME 60 SUBJECTS DURING AND AFTER THE CIPROFLOXACIN EXPOSURE. 3. CHARACTERIZE THE EFFECTS OF CIPROFLOXACIN ON THE MOBILIZATION OF AMR GENES IN SYNTHETIC, HUMAN GUT-DERIVED MICROBIAL COMMUNITIES IN VITRO. WE ARE PROPAGATING PRE-EXPOSURE FECAL COMMUNITIES EX VIVO FROM ALL 60 SUBJECTS, AS WELL AS GENERATING COMPLEX, SYNTHETIC COMMUNITIES FROM PRE-EXPOSURE SAMPLES OF 5 SUBJECTS, AND THEN PASSAGING BOTH BULK AND SYNTHETIC COMMUNITIES ANAEROBICALLY UNDER MULTIPLE CIPROFLOXACIN REGIMES. WE ARE IDENTIFYING FACTORS AND CONDITIONS THAT AFFECT EMERGENCE OF AMR THROUGH HGT AND DE NOVO MUTATIONS IN VITRO.ACCOMPLISHMENTS: 1. STOOL SAMPLES FROM 60 SUBJECTS WERE EXTRACTED AND SEQUENCED. 2. HI-C DNA LIBRARIES ARE BEING CONSISTENTLY GENERATED. NEW COMPUTATIONAL APPROACHES HAVE BEEN DEVELOPED THAT WORK DIRECTLY FROM METAGENOMIC DATA TO RECOVER EXTRA-CHROMOSAL MGES (ECMGES). A NEW TOOL FOR RECONSTRUCTING ECMGE GENOMES FROM METAGENOMIC DATA WAS CREATED. 3. FACS SORTING APPROACH FOR OBTAINING GUT ISOLATES HAS BEEN DRAMATICALLY IMPROVED. SYSTEMATIC STUDY OF NUTRIENT AVAILABILITY AND COMMUNITY COMPOSITION PROVIDES A PREDICTIVE FRAMEWORK THAT WILL AID IN RATIONAL DESIGN OF COMMUNITIES FOR STUDYING HGT OF AMR GENES AND HAS ESTABLISHED THE LAB'S ABILITY TO MODEL VARIOUS HUMAN FECAL SAMPLES WITH COMMUNITIES IN VITRO. 20244621 3221296 PAVIR IS PRIVILEGED TO WORK WITH A LARGE COMMUNITY OF UNIQUELY TALENTED MEDICAL RESEARCHERS ACROSS A BROAD SPECTRUM OF RESEARCH AREAS AS WE FULFILL OUR MISSION OF ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. THE RANGE OF RESEARCH ACTIVITIES IS BROAD AND INCLUDES SPECIAL EMPHASIS ON MAJOR DISEASE CATEGORIES, ALL OF WHICH ARE PREVALENT IN THE VA'S PATIENT POPULATION. THESE INCLUDE CARDIOVASCULAR MEDICINE, MENTAL HEALTH, CHRONIC INFLAMMATORY DISEASE, STEM CELL/REGENERATIVE MEDICINE, PAIN, SLEEP DISORDERS, AND MANY OTHERS. IN ADDITION TO DISEASE SPECIFIC RESEARCH, PAVIR IS ENGAGED IN SUPPORTING RESEARCH AIMED AT ENHANCING HEALTH CARE. PAVIR'S RESEARCH PORTFOLIO INCLUDES COMPARATIVE STUDIES IN WHICH RESEARCH TEAMS ARE LEARNING WHICH TREATMENTS ARE SUPERIOR TO OTHERS, HOW TO AUGMENT OR IMPROVE STANDARD OF CARE, AS WELL AS HOW TO ENHANCE THE OPERATION OF HEALTH CARE. FURTHERMORE, PAVIR IS SUPPORTING EDUCATIONAL ACTIVITIES, ESPECIALLY IN AREAS OF ADVANCING CLINICAL CARE FOR VETERANS AND FOSTERING THE PROFESSIONAL DEVELOPMENT OF OUR EXPERT STAFF. 20244621 3221296 23433313 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 44 0 1 273 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 2 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X LILY IBRAGIMOV 6502392805 3801 MIRANDA AVENUE PALO ALTO CA 94304 X LISA HOWARD STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 MEGHAN KEMNEC ND STATUTORY NON-VA DIRECTOR 0.50 X 0 0 0 MIKE KOZAL MD STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 PAUL HEIDENREICH DIRECTOR, SECRETARY/TREASURER 1.00 40.00 X X 0 0 0 LAWRENCE LEUNG DIRECTOR/AUDIT COMMITTEE CHAIR 1.00 40.00 X 0 0 0 DAVID J CLARK DIRECTOR, BOARD CHAIR 1.00 40.00 X X 0 0 0 ODETTE HARRIS MD MPH DIRECTOR UNTIL 8/31/21 0.50 40.00 X 0 0 0 ANDREW R HOFFMAN MD DIRECTOR 0.50 40.00 X 0 0 0 PHILIP TSAO DIRECTOR 1.00 40.00 X 0 0 0 MARK NICOLLS DIRECTOR 1.00 40.00 X 0 0 0 FERID MURAD DIRECTOR 0.50 X 47492 0 4274 JOHN POLLARD STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 ROBERT SLOSS STATUTORY NON-VA DIRECTOR 0.50 X 0 0 0 JENNIFER LEE STATUTORY VA DIRECTOR 1.00 40.00 X 0 0 0 THOMAS J FITZGERALD III STATUTORY VA DIRECTOR UNTIL 1/31/21 0.50 40.00 X 0 0 0 RINA N SHAH STATUTORY VA DIRECTOR UNTIL 2/28/21 0.50 40.00 X 0 0 0 CHARLIE CONZ STATUTORY NON-VA DIR. UNTIL 01/13/21 0.50 X 0 0 0 MICHAEL ANTHONY HINDERY CEO UNTIL 9/1/21 40.00 X 286211 0 37458 LISA CLARK HR DIRECTOR 40.00 X 171978 0 16561 LILY IBRAGIMOV DIRECTOR OF FINANCE & ACCOUNTING 40.00 X 160590 0 25599 ELAINE STAATS DIRECTOR OF SPONSORED RESEARCH 40.00 X 154949 0 35730 WEN AMY TIAN RESEARCH SCIENTIST II 40.00 X 147369 0 11520 MARY L THORNTON DIRECTOR OF DATA INTEGRITY 40.00 X 144762 0 24132 MAHEEN ADAMSON PRINCIPAL INVESTIGATOR II 40.00 X 142984 0 13074 XINGUO JIANG RESEARCH SCIENTIST II 40.00 X 139412 0 31039 CUIPING PAN BUSINESS DEVELOPMENT MANAGER III 40.00 X 137430 0 13880 1533177 0 213267 9 0 1 0 0 22643899 1826456 24470355 GOVERNMENT FEES & CONTRACTS 541700 2591113 2591113 MEDICAL RESEARCH 541700 2285785 2285785 4876898 17582 17582 66941 67564 -623 -623 -623 MISCELLANEOUS INCOME 900099 35800 35800 35800 29400012 4876898 0 52759 968578 51766 916812 12179694 9666107 2513587 821621 633446 188175 1059383 842531 216852 1024361 773352 251009 42537 9164 33373 87911 87911 1122648 1050898 71750 23123 20508 2615 523237 325984 197253 28544 28544 7292 7292 202833 172610 30223 273587 258434 15153 56345 56345 SUBRECIPIENTS 3953428 3953428 RESEARCH MATERIAL COST 2774868 2774868 OTHER PERSONNEL COST 2694507 2610405 84102 EQUIPMENT MAINTENANCE 180449 179098 1351 93995 74878 19117 28118941 23433313 4685628 0 1823799 1418346 5999388 9417233 4029336 3294258 214129 268015 3952069 3159948 915754 792121 12982406 15189973 4155963 3789802 1409314 3389862 700000 11482 6265277 7191146 X 5271449 5040085 1445680 2958742 6717129 7998827 12982406 15189973 1281071 627 0 X 0 1 X 1 1 1 X VA PALO ALTO HEALTH CARE SYSTEM PALO ALTO CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3952069 3159948 792121 792121 X 29400639 627 627 29400012 0 29400012 28118941 0 28118941 0 28118941 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT CORPORATION EXEMPT FROM FEDERAL INCOME TAX UNDER INTERNAL REVENUE CODE SECTION 501(C)(3) AND STATE INCOME TAX UNDER CALIFORNIA REVENUE AND TAXATION CODE SECTION 23701D. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER IRC SECTION 170(B)(1)(A)(III) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A)(1). AS OF SEPTEMBER 30, 2021 AND 2020, THE ORGANIZATION HAD NO UNRECOGNIZED TAX BENEFITS OR UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL. THEREFORE, NO PROVISION FOR INCOME TAXES HAS BEEN PROVIDED IN THE FINANCIAL STATEMENTS. X X 0 0 0 0 0 0 0 0 0 MICHAEL ANTHONY HINDERY CEO UNTIL 9/1/21 286211 0 0 0 0 0 25650 0 11808 0 323669 0 0 0 ELAINE STAATS DIRECTOR OF SPONSORED RESEARCH 154949 0 0 0 0 0 15203 0 20527 0 190679 0 0 0 LISA CLARK HR DIRECTOR 171978 0 0 0 0 0 15494 0 1067 0 188539 0 0 0 LILY IBRAGIMOV DIRECTOR OF FINANCE & ACCOUNTING 160590 0 0 0 0 0 14819 0 10780 0 186189 0 0 0 XINGUO JIANG RESEARCH SCIENTIST II 139412 0 0 0 0 0 13270 0 17769 0 170451 0 0 0 MARY L THORNTON DIRECTOR OF DATA INTEGRITY 144762 0 0 0 0 0 13394 0 10738 0 168894 0 0 0 WEN AMY TIAN RESEARCH SCIENTIST II 147369 0 0 0 0 0 11026 0 494 0 158889 0 0 0 MAHEEN ADAMSON PRINCIPAL INVESTIGATOR II 142984 0 0 0 0 0 9173 0 3901 0 156058 0 0 0 CUIPING PAN BUSINESS DEVELOPMENT MANAGER III 137430 0 0 0 0 0 12420 0 1460 0 151310 0 0 0 FORM 990, PART VI, SECTION A, LINE 7A PAVIR IS A NONPROFIT CORPORATION AUTHORIZED BY TITLE 38 US CODE SECTIONS 7361 THROUGH 7366 TO BE ESTABLISHED AT AND AFFILIATED WITH THE DEPARTMENT OF VETERANS AFFAIRS PALO ALTO HEALTH CARE SYSTEM (VAPAHCS). THE REFERENCED STATUTE DICTATES THAT FOUR DIRECTORS SHALL BE THOSE PERSONS HOLDING THE VAPAHCS POSITIONS OF DIRECTOR, CHIEF OF STAFF, ASSOCIATE CHIEF OF STAFF FOR RESEARCH AND ASSOCIATE CHIEF OF STAFF FOR EDUCATION. FORM 990, PART VI, SECTION A, LINE 7B AS STATED IN RESPONSE TO FORM 990, PART VI, LINE 7A ABOVE, VA HAS AUTHORITY TO IMPOSE REQUIREMENTS AND RESTRICTIONS ON THE ORGANIZATION THROUGH THE REFERENCED STATUTE AND REGULATIONS PRESCRIBED BY THE SECRETARY OF VETERANS AFFAIRS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 HAS BEEN PROVIDED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO THE FILING OF RELATED TAX FORMS. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS, OFFICERS AND KEY EMPLOYEES COMPLETE TRAINING IN AND ATTEST TO COMPLIANCE WITH PAVIR'S CONFLICT OF INTEREST POLICY, AS WELL AS DISCLOSING INTERESTS WHICH COULD GIVE RISE TO CONFLICTS, UPON JOINING PAVIR AND ANNUALLY THEREAFTER. MANAGEMENT TRACKS THE DATES, SENDS REMINDERS AND DOCUMENTS RECEIPT OF TRAINING, ATTESTATIONS, AND DISCLOSURES, ASSURING COMPLIANCE IN EACH CALENDAR YEAR. FORM 990, PART VI, SECTION B, LINE 15 ANNUALLY, PAVIR COLLECTS AND ANALYZES MARKET, SALARY SURVEY AND COMPENSATION STUDY DATA BASED ON COMPARABLE INDUSTRY AND REVENUE. THE BOARD'S COMPENSATION COMMITTEE REVIEWS THE DATA, TAKING INTO ACCOUNT PERFORMANCE AND ACCOMPLISHMENTS WHEN ESTABLISHING THE CEO'S COMPENSATION. THE COMPENSATION COMMITTEE KEEPS MINUTES OF ITS MEETINGS AND REPORTS ITS ACTIONS TO THE FULL BOARD. KEY EMPLOYEES' SALARIES ARE SET BY THE CEO UTILIZING INFORMATION FROM PAVIR'S ANNUAL SALARY SCHEDULES. FORM 990, PART VI, SECTION C, LINE 19 THE AUDITED FINANCIAL STATEMENTS, ORGANIZING/GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON WRITTEN REQUEST. FORM 990, PART VII AND SCHEDULE J, PART II: ON 03/07/22, THE CEO WROTE TO EACH OF THE 13 BOARD MEMBERS WHO ARE COMPENSATED BY THE VA PALO ALTO HEALTH CARE SYSTEM REQUESTING PERMISSION TO OBTAIN HIS/HER COMPENSATION INFORMATION FOR THE TAX YEAR ENDING 12/31/20. IN RESPONSE, ALL BOARD MEMBERS DECLINED IN WRITING TO PROVIDE THEIR COMPENSATION INFORMATION. NONE OF THE BOARD MEMBERS RECEIVE COMPENSATION IN RELATION TO THEIR DUTIES AS BOARD MEMBERS OF PAVIR. VA PALO ALTO HEALTH CARE SYSTEM 3801 MIRANDA AVENUE PALO ALTO CA 94304 941179505 TEACHING HOSPITAL, PROVIDING A FULL RANGE OF PATEINT CARE SERVICES CA 501(C)(1) N/A 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0